

# **2016** URAC DISEASE MANAGEMENT PERFORMANCE MEASUREMENT:

AGGREGATE SUMMARY PERFORMANCE REPORT

December 2016

# Table of Contents

# Table of Exhibits

Exhibit 1: Regional Areas Served	2
Exhibit 2: Eligible Population per Disease Management Program Measure	2
Exhibit 3: Aggregate Rate by Measure – Commercial Population	3
Exhibit 4: Aggregate Rate by Measure – All Other Population	3
Exhibit 5: Percentage of Participants Screened for Tobacco Use	1
Exhibit 6: Screening and Cessation Counseling for Tobacco Use (Summary Data, Benchmarks, and Percentiles)	
Exhibit 7: Percentage of Participants Screened for Unhealthy Alcohol Use	5
Exhibit 8: Screening for Unhealthy Alcohol Use (Summary Data, Benchmarks, and Percentiles)	5
Exhibit 9: Percentage of Participants (w/ BMI ≥25) Who Received Counseling for Weight Management	3
Exhibit 10: Prevention and Management of Obesity for Adults (Summary Data, Benchmarks, and Percentiles)	3
Exhibit 11: Percentage of Patients Screened for Clinical Depression	7
Exhibit 12: Screening for Clinical Depression (Summary Data, Benchmarks, and Percentiles)	7
Exhibit 13: Percentage of Participants (Age 18-75) Discharged from Hospital with Asthma 8	3

Exhibit 14: Adult Asthma Event Rate (Summary Data, Benchmarks, and Percentiles) 8
Exhibit 15: Percentage of Participants (Age 2-17) Discharged from Hospital with Asthma 9
Exhibit 16: Pediatric Asthma Event Rate (Summary Data, Benchmarks, and Percentiles)9
Exhibit 17: Percentage of Participants (Age ≥40) Discharged from Hospital with COPD or Asthma10
Exhibit 18: Chronic Obstructive Pulmonary Disease (Summary Data, Benchmarks, and Percentiles)10
Exhibit 19: Percentage of Participants Discharged from Hospital with Hypertension11
Exhibit 20: Hypertension Event Rate (Summary Data, Benchmarks, and Percentiles)11
Exhibit 21: Percentage of Participants Discharged from Hospital with Heart Failure12
Exhibit 22: Heart Failure Event Rate (Summary Data, Benchmarks, and Percentiles)12
Exhibit 23: Percentage of Participants Discharged with Evidence of Short-Term Diabetes13
Exhibit 24: Diabetes Short-Term Complications Event Rate (Summary Data, Benchmarks, and Percentiles)
Exhibit 25: Percentage of Participants Who Met Proportion of Days Covered Threshold (80%) 14
Exhibit 26: Proportion of Days Covered (Summary Data)14
Exhibit 27: Medication Therapy for Persons with Asthma – All Other Population Only15

# **Executive Summary**

Presented in this report are the 2015 measurement year results on URAC's Disease Management (DM) Accreditation measures. Only the aggregate summary rates are presented and no individual performance results are identified for public reporting.

Organizations were required to report data for 10 mandatory measures, and they had the option to report data for two exploratory measures. The measures are either cross-cutting (i.e., broadly applicable across multiple clinical settings or specialties) or disease-specific (i.e., applicable to a specific condition). Below is the list of mandatory [M] and exploratory [E] measures for 2016 reporting with indication of whether the measure is cross-cutting or disease-specific:


- 1. Screening and Cessation Counseling for Tobacco Use (DM2012-02) [M] Cross-Cutting
- 2. Screening for Unhealthy Alcohol Use (DM2012-03) [M] Cross-Cutting
- 3. Prevention and Management of Obesity for Adults (DM2012-04) [M] Cross-Cutting
- 4. Screening for Clinical Depression (DM2012-05) [M] Cross-Cutting
- 5. Adult Asthma Event Rate (DM2012-29) [M] Disease-Specific
- 6. Pediatric Asthma Event Rate (DM2012-30) [M] Disease-Specific
- 7. Chronic Obstructive Pulmonary Disease (DM2012-31) [M] Disease-Specific
- 8. Hypertension Event Rate (DM2012-37) [M] Disease-Specific
- 9. Heart Failure Event Rate (DM2012-38) [M] Disease-Specific
- 10. Diabetes Short-Term Complications Event Rate (DM2012-73) [M] Disease-Specific
- 11. Proportion of Days Covered (DM2012-12) [E] Cross-Cutting
- 12. Medication Therapy for Persons with Asthma (DM2012-26) [E] Disease-Specific

While not indicated in the report, it is recommended that future data collection efforts include data quality checks to ensure correct numerators, denominators, and rate formats are entered by organizations. With manual data review and cleaning, data entry errors were corrected and noted in the data files. There were no material issues impacting the calculation of aggregate statistics and benchmarks in this report. Respondents will be notified in the individual reports where data entry corrections were made.

# **Results: Disease Management General Questions**


Thirteen URAC accredited Disease Management organizations reported 2015 measurement year data for the 2016 reporting year. One organization provided only plan characteristics and no measure results. Nine organizations reported Commercial results, and three organizations reported All Other Population results.

The Midwest (85%, n=11) represented the largest population served by the organizations, and the West (46%, n=6) represented the least. The total number of unique individuals eligible for disease management ranges from 788 to 1,200,000 members across the respondent organizations with a median population of 4,451.




#### Exhibit 1: Regional Areas Served

Note: Multiple responses accepted.




#### Exhibit 2: Eligible Population per Disease Management Program Measure



#### Exhibit 3: Aggregate Rate by Measure - Commercial Population






## **Results: Disease Management Measures**

Twelve of the 13 organizations reported data for at least one of the performance measures. The organizations are primarily classified as Commercial programs, but in some cases organizations were not able to stratify by Commercial, Medicaid, and Medicare, and thus were classified as All Other Populations. The analysis results are included for each measure. Due to limited number of organizations that reported as All Other Populations, aggregate data analysis was not performed and (i.e., benchmark and percentiles were not produced).

#### Measure 1 – Screening and Cessation Counseling for Tobacco Use (DM2012-02)

#### **Measure Description:**

This measure assesses the percentage of participants who were screened for tobacco use at least once during the measurement period and who received cessation counselling intervention, if identified as a tobacco user.



#### Exhibit 5: Percentage of Participants Screened for Tobacco Use

#### **Summary of Findings:**

Nine organizations submitted data for Commercial and two organizations for All Other Population. The median is 31.8%, and low performing organizations with large denominators skew the aggregate rate to the left. The Commercial results are strongly influenced by Response ID # 37 given the denominator size of 39,705 (Rate = 1.01%) compared to the median denominator size of 964.


Exhibit 6: Screening and Cessation Counseling for Tobacco Use (Summary Data, Benchmarks, and Percenti				
	Exhibit 6. Screening and Cossistion (	Counseling for Tobacco	o Lleo (Summary Data	Renchmarke and Percentiles)
	Exhibit 0. Objectning and Dessation v		0 036 (Ourninary Data	, Denominarks, and references)

		Tot	al	Total	Aggregate	Number of
		Nume	rator De	enominator	Sum Rate	Reports
Commercial		6,44	45	51,971	12.4%	9
All Other Po	pulation	19	190 1,310		14.5%	2
Benchmarks and Percentiles (Commercial Only)						
Min	10 <sup>th</sup>	25 <sup>th</sup>	50 <sup>th</sup>	75 <sup>th</sup>	90 <sup>th</sup>	Max
1.0%	1.8%	11.1%	31.8%	72.6%	88.4%	90.8%

#### Measure 2 – Screening for Unhealthy Alcohol Use (DM2012-03)

#### **Measure Description:**

This measure assesses the percentage of participants 18 years or older who were screened for unhealthy alcohol use at least once during the measurement period using a systematic screening method and who received brief counseling, if identified as an unhealthy alcohol user.





#### **Summary of Findings:**

Eight organizations submitted data for Commercial and two organizations for All Other Population. The aggregate rate for Commercial is strongly influenced by Response ID # 37 given the denominator size of 39,412 (Rate = 0.01%) compared to the median denominator size of 822. The median is 52.5% and low performing organizations with large denominators skew the aggregate rate to the left. The Commercial results are strongly influenced by Response ID # 37 given the denominator size of 39,412 (Rate = 0.01%) compared to the median denominator skew the aggregate rate to the left. The Commercial results are strongly influenced by Response ID # 37 given the denominator size of 39,412 (Rate = 0.01%) compared to the median denominator size of 822.

		Tot		Total	Aggregate	Number of	
		Nume	rator D	Denominator	Sum Rate	Reports	
Commercial		5,57	75	47,480	11.7%	8	
All Other Po	pulation	46	7	1,377	33.9%	2	
Benchmarks and Percentiles (Commercial Only)							
Min	10 <sup>th</sup>	25 <sup>th</sup>	50 <sup>th</sup>	75 <sup>th</sup>	90 <sup>th</sup>	Max	
0.0%	0.4%	2.4%	52.5%	90.6%	92.5%	95.7%	


Exhibit 8: Screening for Unhealthy Alcohol Use (Summary Data, Benchmarks, and Percentiles)

#### Measure 3 – Prevention and Management of Obesity for Adults (DM2012-04)

#### **Measure Description:**

This measure assesses the percentage of participants 18 years or older with a documented body mass index (BMI) greater than or equal to 25 who received education and counseling for weight loss strategies that include nutrition, physical activity, lifestyle changes, medication therapy, and/or surgical considerations during the measurement period.

Exhibit 9: Percentage of Participants (w/ BMI ≥25) Who Received Counseling for Weight Management



#### **Summary of Findings:**

Nine organizations submitted data for Commercial and three organizations for All Other Population. The aggregate rate for Commercial is strongly influenced by Response ID # 37 given the denominator size of 5,068 (Rate = 5.35%) compared to the median denominator size of 660.

Exhibit 10: Prevention and Management of	Obesity for Adults (Summa	ary Data, Benchmarks, and Percentiles)


		Tot	al	Total	Aggregate	Number of	
		Nume	rator Den	ominator	Sum Rate	Reports	
Commercial	mmercial 3,249		49 1	1,867	27.4%	9	
All Other Po	All Other Population 417		7	637	65.5%	3	
Benchmarks and Percentiles (Commercial Only)							
Min	10 <sup>th</sup>	25 <sup>th</sup>	50 <sup>th</sup>	75 <sup>th</sup>	90 <sup>th</sup>	Max	
5.4%	10.7%	28.0%	44.9%	81.0%	86.0%	96.7%	

### Measure 4 – Screening for Clinical Depression (DM2012-05)

#### **Measure Description:**

This measure reports the percentage of participants 12 years and older screened for clinical depression on the date of the encounter using a standardized tool and if positive, a follow-up plan documented during the measurement period.





#### **Summary of Findings:**

Eight organizations submitted data for Commercial and two organizations for All Other Population for this measure. The aggregate rate for Commercial is strongly influenced by Response ID # 37 given the denominator size of 6,173 (Rate = 2.92%) compared to the median denominator size of 1,504.


Exhibit 12: Sorooping for Cli	ical Doproceion (Summory Doto	, Benchmarks, and Percentiles)
EXHIBIT 12. SCIERING IOF CII	ical Deplession (Summary Data	. Denominarks, and Fercenties)

		Tot	al	Total	Aggregate	Number of	
		Nume	rator De	nominator	Sum Rate	Reports	
Commercial		3,900		14,839	26.3%	8	
All Other Po	pulation	50	2	1,337	37.6%	2	
Benchmarks and Percentiles (Commercial Only)							
Min	10 <sup>th</sup>	25 <sup>th</sup>	50 <sup>th</sup>	75 <sup>th</sup>	90 <sup>th</sup>	Max	
2.0%	2.6%	10.6%	40.2%	83.3%	95.8%	98.2%	

#### Measure 5 – Adult Asthma Event Rate (DM2012-29)

#### **Measure Description:**

This measure assesses the number of hospital events for asthma per number of adult asthmatic members as of the end of the measurement period.





#### **Summary of Findings:**

Eight organizations submitted data for Commercial and three organizations for All Other Population for this measure. The aggregate rate for Commercial is strongly influenced by Response ID #37 given the denominator size of 578 (Rate = 5.88%) compared to the median denominator size of 89. The overall results show high performance with few hospitalizations.


Exhibit 14: Adult Asthma Event Rate	(Summary Data,	, Benchmarks, and Percentiles)	)
-------------------------------------	----------------	--------------------------------	---


		Tot	al	Total	Aggregate	Number of	
		Nume	rator	Denominator	Sum Rate	Reports	
Commercial	nercial 74		1	1,428	5.2%	8	
All Other Po	pulation	10	2	2,208	4.6%	3	
	Benchmarks and Percentiles (Commercial Only)						
Min	90 <sup>th</sup>	75 <sup>th</sup>	50 <sup>th</sup>	25 <sup>th</sup>	10 <sup>th</sup>	Max	
0.0%	0.0%	0.3%	4.4%	5 10.0%	39.3%	85.7%	

#### Measure 6 – Pediatric Asthma Event Rate (DM2012-30)

#### **Measure Description:**

This measure assesses the number of hospital events for asthma per number of asthmatic children ages 2 to 17 as of the end of the measurement period.





#### **Summary of Findings:**

Six organizations submitted data for Commercial and three organizations for All Other Population for this measure. The aggregate rate for Commercial is strongly influenced by Response ID # 37 given the denominator size of 169 (Rate = 6.51%) compared to the median denominator size of 36. Four of the six Commercial organizations did not have any numerator events for hospitalization. The overall results show high performance with few hospitalizations with small variation between organizations.

		Tot Nume		Total ominator	Aggregate Sum Rate	Number of Reports		
Commercial		15	5	374	4.0%	6		
All Other Population		10	8	1,168	9.3%	3		
	Benchmarks and Percentiles (Commercial Only)							
Min	90 <sup>th</sup>	75 <sup>th</sup>	50 <sup>th</sup>	25 <sup>th</sup>	10 <sup>th</sup>	Max		
0.0%	0.0%	0.0%	0.0%	2.7%	5.0%	6.5%		


Exhibit 16: Pediatric Asthma Event Rate (Summary Data, Benchmarks, and Percentiles)

#### Measure 7 – Chronic Obstructive Pulmonary Disease (DM2012-31)

#### **Measure Description:**

This measure assesses the number of hospital events for Chronic Obstructive Pulmonary Disease (COPD) or asthma per number of adult members age 40 years old or older with a diagnosis of COPD or asthma.





#### Summary of Findings:

Eight organizations submitted data for Commercial and two organizations for All Other Population for this measure. The aggregate rate for Commercial is strongly influenced by Response ID # 37 given the denominator size of 333 (Rate = 10.81%) compared to the median denominator size of 100. The overall results show high performance with few hospitalizations.


Exhibit 18: Chronic Obstructive Pulmonary	v Disease (Sum	marv Data, Benchmark	s. and Percentiles)
Exhibit for officine obourdeuro i differida	, Dioodoo (Odini	mary Bala, Bomorninan	

		Tot	al	Total	Aggregate	Number of			
		Nume	rator Der	ominator	Sum Rate	Reports			
Commercial	Commercial		84		8.2%	8			
All Other Population		68	68 2,		3.1%	3			
	Benchmarks and Percentiles (Commercial Only)								
Min	90 <sup>th</sup>	75 <sup>th</sup>	50 <sup>th</sup>	25 <sup>th</sup>	10 <sup>th</sup>	Max			
0.0%	0.0%	1.0%	6.3%	17.8%	29.4%	46.2%			

### Measure 8 – Hypertension Event Rate (DM2012-37)

#### **Measure Description:**

This measure assesses the number of hospital events for hypertension per number of adult members with hypertension during the measurement period.





#### Summary of Findings:

Eight organizations submitted data for Commercial and two organizations for All Other Population for this measure. The aggregate rate for Commercial is strongly influenced by Response ID # 26 given the denominator size of 2,614 (Rate = 1.42%) compared to the median denominator size of 560. The overall results show high performance with few hospitalizations and small variation between organizations.


Exhibit 20: Hypertension Event Rate (Summary	/ Data, Benchmarks, and Percentiles)
--	--------------------------------------

		Tot		Total	Aggregate	Number of			
		Nume	rator Den	ominator	Sum Rate	Reports			
Commercial		13	7	8,061	1.7%	8			
All Other Po	All Other Population		2	3,604	9.7%	2			
	Benchmarks and Percentiles (Commercial Only)								
Min	90 <sup>th</sup>	75 <sup>th</sup>	50 <sup>th</sup>	25 <sup>th</sup>	10 <sup>th</sup>	Max			
0.0%	0.0%	0.4%	1.6%	10.2%	11.3%	12.0%			

### Measure 9 – Heart Failure Event Rate (DM2012-38)

#### **Measure Description:**

This measure assesses the number of hospital events with a principal diagnosis of heart failure per number of adult members with diagnosed heart failure.





#### Summary of Findings:


Nine organizations submitted data for Commercial and two organizations for All Other Population for this measure. The aggregate rate for Commercial is strongly influenced by Response ID # 26 given the denominator size of 2,614 (Rate = 0.88%) compared to the median denominator size of 17. The overall results show high performance with few hospitalizations and small variation between organizations.

		Tot Nume		Total nominator	Aggregate Sum Rate	Number of Reports		
Commercial	Commercial		2	3,604	2.6%	9		
All Other Po	All Other Population		L .	1,095	4.9%	2		
	Benchmarks and Percentiles (Commercial Only)							
Min	90 <sup>th</sup>	75 <sup>th</sup>	50 <sup>th</sup>	25 <sup>th</sup>	10 <sup>th</sup>	Max		
0.0%	0.0%	0.0%	0.9%	9.1%	10.4%	11.8%		

#### Measure 10 – Diabetes Short-Term Complications Event Rate (DM2012-73)

#### **Measure Description:**

This measure assesses the number short-term diabetes complication events (ketoacidosis, hyperosmolarity, or coma) in adults per number of adult members as of the end of the measurement period.





#### Summary of Findings:

Nine organizations submitted data for Commercial and two organizations for All Other Population for this measure. Response ID # 43 had a high rate of 31.9%, but did not impact the aggregate rate given the denominator size of 69 compared to the median denominator size of 443. The overall results show high performance.

Exhibit 24: Diabetes Short-Term Complications Event Rate (Summary Data, Benchmarks, and Percentiles)


		Tot Nume		Total ominator	Aggregate Sum Rate	Number of Reports		
Commercial		10	3 6	6,766	1.5%	9		
All Other Population		35	35		8.7%	2		
Benchmarks and Percentiles (Commercial Only)								
Min	90 <sup>th</sup>	75 <sup>th</sup>	50 <sup>th</sup>	25 <sup>th</sup>	10 <sup>th</sup>	Max		
0.0%	0.0%	0.5%	1.6%	2.3%	9.9%	31.9%		

#### Measure 11 – Proportion of Days Covered (DM2012-12)

#### **Measure Description:**

This measure assesses the percentage of participants 18 years and older who met the proportion of days covered (PDC) threshold of 80% during the measurement period. A separate rate is calculated for the following medications: Beta-blocker, Renin Angiotensin System Antagonists, Calcium Channel Blocker, Statin, Biguanide, Sulfonylurea, Thiazolidinedione, DiPeptidyl Peptidase-IV Inhibitor, Diabetes All Class, Antiretroviral (this measure has a threshold of 90% for at least 2 medications).





#### **Summary of Findings:**

Only one organization submitted data for Commercial category for Proportion of Days Covered. No other organizations submitted data in other categories for this measure.


	Numerator	Numerator Denominator	
Rate 1	283	328	86.28%
Rate 2	590	668	88.32%
Rate 3	170	193	88.08%
Rate 4	195	227	85.90%
Rate 5	52	55	94.55%
Rate 6	9	11	81.82%
Rate 7	24	29	82.76%
Rate 8	221	252	87.70%
Rate 9	507	593	85.50%

Exhibit 26: Dro	nortion of Do	va Covarad (	Summony	Data)
Exhibit 26: Pro	portion of Da	ys Covereu (	Summary	Dala)

#### Measure 12 – Medication Therapy for Persons with Asthma (DM2012-26)

#### **Measure Description:**

This measure assesses the percentage of participants with asthma who were dispensed more than 3 canisters of a short-acting beta2 agonist inhaler over a 90-day period and who did not receive controller therapy during the same 90-day period.





#### Summary of Findings:

Only one organization submitted data for All Other Population category for Medication Therapy for persons with Asthma. The sample size was 31 with 11 participants for both rates (Suboptimal Asthma Control and Absence of Controller Therapy). No other organizations submitted data in the Commercial category for this measure.

# **Concluding Remarks**

This performance report has been prepared by the URAC Quality, Research, and Measurement Department. If you have any questions about the results contained herein, please contact us at: <u>ResearchMeasurement@urac.org</u>.